irak1bp1 Antibody

What is IRAK1BP1 and what is its biological function?

IRAK1BP1 functions as a key negative regulator of inflammation through its effects on NF-κB signaling. It down-modulates Toll-like receptor (TLR)-mediated transcription of several proinflammatory cytokines by altering the transcriptional profile of activated cells . Rather than broadly inhibiting signaling pathways, IRAK1BP1 promotes increased IL-10 production and LPS tolerance . At the molecular level, IRAK1BP1 influences the ratio of NF-κB subunit dimers, increasing p50/p50 homodimers relative to p50/p65 heterodimers . This effect correlates with IRAK1BP1's ability to bind the p50 precursor molecule p105 . Through these mechanisms, IRAK1BP1 serves as a molecular switch that helps resolve inflammation after pathogen clearance.

What are the characteristics of available IRAK1BP1 antibodies?

Available IRAK1BP1 antibodies vary in their format, host species, and conjugation status. Most commercial antibodies are rabbit polyclonal antibodies targeting epitopes within amino acids 51-150 of the 260-amino acid human IRAK1BP1 protein . These antibodies are available in several formats:

• Unconjugated antibodies for standard detection methods

• Biotinylated antibodies for signal amplification systems

• Fluorophore-conjugated versions (including AbBy Fluor® 350, AbBy Fluor® 488, APC) for direct visualization in fluorescence applications

Most IRAK1BP1 antibodies demonstrate reactivity with human and mouse samples, with predicted reactivity in rat and rabbit samples based on sequence homology .

What applications are IRAK1BP1 antibodies validated for?

IRAK1BP1 antibodies have been validated for multiple research applications, including:

• Western blotting (WB): For detecting IRAK1BP1 protein in cell or tissue lysates, typically at dilutions ranging from 1:300-5000

• ELISA: For quantitative protein detection

• Immunofluorescence (IF): For both cultured cells (IF-ICC) and tissue sections (IF-IHC-P, IF-IHC-F), typically at dilutions of 1:50-200

• Immunohistochemistry (IHC): For both paraffin-embedded (IHC-P) and frozen sections (IHC-F)

• Immunocytochemistry (ICC): For examining subcellular localization

The selection of appropriate application should be guided by the experimental question, with consideration for the subcellular localization of IRAK1BP1 in both cytoplasm and nucleus .

What cross-reactivity concerns exist with IRAK1BP1 antibodies?

Researchers should be aware that some IRAK1BP1 antibodies may exhibit minor secondary cross-reactivity with SMPD5 (Sphingomyelin Phosphodiesterase 5) due to approximately 63% contiguous sequence similarity over the immunogen range . This potential cross-reactivity highlights the importance of including appropriate controls in experimental designs, particularly when studying tissues or cells that might express both proteins.

Additionally, researchers should be careful to distinguish between IRAK1 and IRAK1BP1, which are distinct proteins despite their related nomenclature. IRAK1 is a serine/threonine protein kinase involved in initiating innate immune responses , while IRAK1BP1 is a binding protein that modulates inflammatory signaling .

How should I validate IRAK1BP1 antibody specificity in my experimental system?

Thorough validation of IRAK1BP1 antibodies is essential for obtaining reliable results. Consider implementing these methodological approaches:

• Genetic validation: Compare staining between wild-type samples and those with IRAK1BP1 knockdown or knockout. The search results mention IRAK1BP1-knockout mice that provide excellent negative controls .

• Peptide competition: Pre-incubate the antibody with the immunizing peptide before application to samples. Specific staining should be significantly reduced or eliminated.

• Cross-reactivity assessment: Be mindful of potential cross-reactivity with SMPD5 . Include controls to distinguish between these proteins if both are expressed in your system.

• Molecular weight verification: In Western blotting, confirm that the detected band appears at the expected molecular weight of approximately 76-77 kDa .

• Subcellular localization: Verify that the staining pattern is consistent with IRAK1BP1's known localization in both cytoplasm and nucleus, which may vary depending on cellular activation state .

• Multiple detection methods: When possible, confirm findings using different techniques (e.g., Western blotting, immunofluorescence) to increase confidence in specificity.

What are the optimal protocols for Western blotting with IRAK1BP1 antibodies?

For effective Western blot detection of IRAK1BP1, consider these methodological considerations:

• Sample preparation: Use lysis buffers containing protease inhibitors to prevent IRAK1BP1 degradation. For studying IRAK1BP1's role in nuclear translocation, consider subcellular fractionation to separately analyze cytoplasmic and nuclear pools .

• Protein loading: Load 15-30 μg total protein per lane, as demonstrated in published protocols . IRAK1BP1 may not be highly abundant in unstimulated cells.

• Gel resolution: Use appropriate percentage gels to resolve proteins in the 75-80 kDa range, as IRAK1BP1 (76 kDa) runs close to IRAK1 (77 kDa) .

• Antibody dilution: Follow manufacturer recommendations for specific antibodies, but typical working dilutions range from 1:300-5000 for Western blotting .

• Incubation conditions: For optimal results, incubate primary antibody at 4°C overnight and perform thorough washing steps between antibody incubations.

• Controls: Include positive control samples (e.g., LPS-stimulated macrophages) and consider using lysates from IRAK1BP1 knockout cells as negative controls .

• Detection method: Choose a detection method with appropriate sensitivity; enhanced chemiluminescence is suitable for most applications.

How can I optimize immunofluorescence/immunohistochemistry for IRAK1BP1 detection?

For optimal immunofluorescence or immunohistochemistry detection of IRAK1BP1:

• Fixation and permeabilization: For cultured cells, paraformaldehyde fixation followed by permeabilization with 0.1% Triton-X100 in 2% BSA has been successfully used for IRAK1BP1 detection .

• Antigen retrieval: For paraffin sections, heat-induced epitope retrieval may be necessary. Try citrate buffer (pH 6.0) or EDTA buffer (pH 9.0).

• Blocking conditions: Use 2% BSA for at least 1 hour at room temperature to reduce non-specific binding .

• Antibody dilution: Use dilutions between 1:50-200 for immunofluorescence and immunohistochemistry applications .

• Incubation time: For primary antibodies, overnight incubation at 4°C is recommended for specific binding .

• Detection systems: For fluorescence applications, antibodies conjugated to fluorophores like AbBy Fluor® 350, AbBy Fluor® 488, or APC can be used for direct detection . For chromogenic detection, appropriate secondary antibodies and substrates should be selected based on the primary antibody host species.

• Nuclear counterstaining: Include DAPI or hematoxylin for nuclear visualization, which helps determine IRAK1BP1's subcellular localization.

How can I use IRAK1BP1 antibodies to study NF-κB pathway modulation?

IRAK1BP1 plays a critical role in modulating NF-κB signaling. To investigate this relationship:

• Co-immunoprecipitation studies: Use IRAK1BP1 antibodies to immunoprecipitate protein complexes and analyze associated NF-κB components. Research shows IRAK1BP1 physically interacts with p105, the precursor of p50 .

• Subcellular fractionation analysis: Separate nuclear and cytoplasmic fractions to assess how IRAK1BP1 affects the nuclear translocation of NF-κB components and the relative abundance of p50/p50 homodimers versus p50/p65 heterodimers .

• Dual immunofluorescence: Co-stain for IRAK1BP1 and NF-κB components (p50, p65) to analyze their spatial relationship within cells under different experimental conditions.

• Functional readouts: Measure downstream effects such as cytokine production profiles, especially focusing on the balance between pro-inflammatory cytokines and IL-10, which is specifically enhanced by IRAK1BP1 activity .

• Time-course experiments: IRAK1BP1's effects on NF-κB signaling are dynamic following stimulation. Design time-course studies to capture the full temporal profile of IRAK1BP1-mediated NF-κB modulation.

What controls are essential when studying IRAK1BP1-NF-κB interactions?

When studying IRAK1BP1-NF-κB interactions, include these critical controls:

• Stimulation controls: Compare unstimulated and stimulated conditions (e.g., LPS, IL-1β) to capture dynamic changes in IRAK1BP1 expression, localization, and interaction with NF-κB components .

• Genetic controls: When available, use IRAK1BP1 knockout or knockdown models to establish baseline NF-κB activity in the absence of IRAK1BP1 .

• Strain considerations: For mouse studies, be aware that different mouse strains have variant IRAK1BP1 alleles with different responsiveness to TLR stimulation. Research indicates the CBA allele is more responsive to TLR activation than other strains .

• Specificity controls: For co-immunoprecipitation studies, include IgG controls and input samples to validate specific interactions between IRAK1BP1 and NF-κB components.

• Functional validation: Include readouts of NF-κB-dependent gene expression, such as cytokine production profiles, to correlate biochemical findings with functional outcomes.

How can I use IRAK1BP1 antibodies to investigate LPS tolerance mechanisms?

LPS tolerance, a state of reduced responsiveness to repeated LPS stimulation, is an important mechanism for resolving inflammation. IRAK1BP1 plays a role in establishing this state . To investigate this phenomenon:

• Sequential stimulation experiments: Design protocols with primary macrophages using an initial low-dose LPS treatment followed by a higher-dose challenge. Use IRAK1BP1 antibodies to monitor expression and localization changes during tolerance induction .

• Genetic correlation studies: Research has shown that the functional allele of IRAK1BP1 is associated with lower levels of IL-6 mRNA after LPS prestimulation, supporting IRAK1BP1's role in establishing tolerance in primary macrophages .

• Time-course experiments: Monitor changes in IRAK1BP1 expression, localization, and interaction partners at different timepoints during tolerance development.

• Cytokine profile analysis: Measure both pro-inflammatory (TNF-α, IL-6) and anti-inflammatory (IL-10) cytokine production in wild-type versus IRAK1BP1-deficient cells during tolerance induction .

• Mechanistic investigations: Use co-immunoprecipitation with IRAK1BP1 antibodies to identify how protein-protein interactions change during tolerance development, particularly focusing on interactions with p105/p50 and other NF-κB pathway components .

What experimental approaches can reveal IRAK1BP1's role in resolving inflammation?

To understand IRAK1BP1's contribution to inflammation resolution:

• Expression kinetics analysis: Use Western blotting with IRAK1BP1 antibodies to track protein expression throughout the inflammatory response, from initiation through resolution phases.

• Nuclear translocation studies: Since IRAK1BP1 affects NF-κB activity through nuclear mechanisms, use fractionation followed by Western blotting or immunofluorescence to monitor its subcellular localization during inflammation resolution .

• Comparative studies with knockout models: Compare the kinetics of inflammation resolution between wild-type and IRAK1BP1-knockout mice or cells to determine how IRAK1BP1 deficiency affects the duration and intensity of inflammatory responses .

• NF-κB dimer composition analysis: Use gel shift assays combined with supershift using specific antibodies to analyze how IRAK1BP1 influences the ratio of p50/p50 homodimers versus p50/p65 heterodimers during inflammation resolution .

• Cytokine production time course: Monitor changes in pro-inflammatory versus anti-inflammatory cytokine production over time, and correlate these changes with IRAK1BP1 expression and localization.

How can I resolve weak or inconsistent IRAK1BP1 detection in Western blots?

When experiencing challenges with IRAK1BP1 detection in Western blots:

• Antibody concentration adjustment: Try increasing antibody concentration within the recommended range (1:300-5000) .

• Protein loading optimization: Increase total protein loading to 15-30 μg per lane as demonstrated in published protocols .

• Enhanced detection systems: Use high-sensitivity chemiluminescent substrates, especially if IRAK1BP1 expression is low in your experimental system.

• Stimulation consideration: IRAK1BP1 expression may increase following inflammatory stimulation. Consider using activated cells (e.g., LPS-stimulated macrophages) as positive controls .

• Membrane transfer optimization: Ensure efficient transfer of higher molecular weight proteins by adjusting transfer conditions (time, voltage, buffer composition).

• Antibody validation: If inconsistent results persist, validate antibody performance using positive control lysates or consider testing alternative antibodies targeting different epitopes of IRAK1BP1.

• Cross-reactivity assessment: Be mindful of the potential cross-reactivity with SMPD5 due to sequence similarity in the immunogen range , which could complicate interpretation of results.

What are common pitfalls in immunofluorescence studies with IRAK1BP1 antibodies?

When performing immunofluorescence with IRAK1BP1 antibodies, be aware of these potential issues:

• Fixation artifacts: Different fixation methods can affect epitope accessibility. Paraformaldehyde fixation (4%) followed by permeabilization with 0.1% Triton X-100 has been successfully used for IRAK1BP1 detection in cultured cells .

• Background fluorescence: Excessive background can obscure specific staining. Optimize blocking with 2% BSA for at least 1 hour at room temperature or try alternative blocking agents if background persists.

• Subcellular localization misinterpretation: IRAK1BP1 can be found in both cytoplasm and nucleus , with distribution changing upon cellular activation. Include nuclear counterstaining with DAPI to accurately interpret localization patterns.

• Cross-reactivity confusion: Be aware of potential cross-reactivity with SMPD5 , which could lead to misinterpretation of staining patterns. Include appropriate controls to distinguish specific from non-specific staining.

• Antibody concentration issues: If signal is weak, try a more concentrated antibody solution within the recommended range (1:50-200 for immunofluorescence) .

• Detection sensitivity limitations: For low-abundance expression, consider signal amplification methods or more sensitive detection systems.